NimBio partners with Takeda Belgium, KU Leuven, and EIT Health to pilot inflammation monitoring for IBD patients

Following successful collaboration through the EIT Health Open Innovation programme, NimBio has signed a Memorandum of Understanding (MoU) with Takeda Belgium, KU Leuven, and EIT Health. Together, we’re launching a clinical pilot to test the Inflammometer, our wearable-powered, AI-driven inflammation monitor, in a real-world hospital setting.

The partnership began when EIT Health brought together healthcare providers and industry experts to identify urgent unmet needs. Both Takeda Belgium and KU Leuven highlighted a shared challenge: detecting IBD flares earlier and enabling more personalised, proactive care.

From more than ten start-ups across Europe, NimBio was selected as the leading solution, offering a non-invasive way to continuously monitor inflammation and detect early signs of a flare before symptoms worsen.

With the pilot now underway, the consortium will test the Inflammometer with KU Leuven patients and explore integration with Takeda’s “For You With You” digital platform. The study aims to gather evidence on how continuous inflammation tracking can improve patient outcomes and reduce healthcare burden.

“This collaboration is about turning innovation into impact,” says Yehuda Chowers, Co-founder of NimBio. “Together, we’re making inflammation visible, and empowering patients to live better.” Read more